October 3, 2013 (CHAPEL HILL, NC) Thought Leader Select, a consulting firm to the life sciences industries, recently earned new work in developing key opinion leader (KOL) strategies in support of new treatments for chronic obstructive pulmonary disorder (COPD) for a top global biopharmaceutical concern.
The client company, one of the world’s top ten industry leaders in the development of medications across multiple therapeutic areas, tabbed North Carolina’s Thought Leader Select to assist them with upcoming and ongoing initiatives with global and national KOLs in the treatment area of COPD.
According to a recent World Health Organization analysis, COPD is now the fourth leading cause of death worldwide after ischemic heart disease, stroke, and lower respiratory infections,
Thought Leader Select, headquartered in the Research Triangle region of North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading medical experts, the health care professionals that advance treatment options and promote better public health at regional, national, and global levels.
Earlier this year, Thought Leader Select provided in-house research resulting in foundational data and analytics to facilitate new KOL relationships for the client company in the field of COPD. This earlier work facilitated a first wave of outreach for the client company to leaders in the COPD community. Based on the success of that first wave initiative, the company returned to Thought Leader Select to expand its KOL outreach to a wider base of leaders in global and national communities.
For the new COPD engagement, Thought Leader Select’s in-house research team will identify dozens of leading medical experts in pulmonology, key opinion leaders at the forefront of research and treatment in the condition. As with all therapeutic area and disease state-driven analyses, Thought Leader Select’s research group will also account for significant work done by notable young and new physicians, also known as rising stars, in the treatment and research for COPD.
After identification, Thought Leader Select will conduct in-depth, comprehensive profiling, in order to offer the client company a broad, deep understanding of the skills and experience, as well as the clinical and research interests of the new roster of key opinion leaders, many of whom will assist the company in the ongoing development of new medicines for the treatment of COPD.
The profiling work will serve as an objective, validated analytics foundation for understanding the professional social networks of the key opinion leaders through Thought Leader Select’s Professional Impact Network (PINs) mapping service. With PINs, Thought Leader Select shows known collaborations among KOLs in key areas of thought leadership that advance medical science, such as publishing in scientific journals, basic and clinical research, and advisory board work.
Thought Leader Select’s post-research advisory support will include advising the company on strategic subjects such as advisory board and consultant selection, as well as KOL collaborations in publications and conference planning, patient advocacy work, and many other areas.
“Thought Leader Select is honored to have another opportunity that will impact public health at a global level,” stated Neil Mellor, the company’s global business development consultant based in Toronto. “While many of our corporate stakeholders have employed Thought Leader Select to find the difference-makers in rare disease and orphan drug areas, we’ve had the opportunity to collaborate with dozens of large pharma and biotech firms in areas like HIV/AIDs, diabetes, and COPD—the areas where new treatments can make a huge difference in health outcomes and quality of life for millions at a time. We are proud to continue our own collaboration with a great company, ensuring that they work an ever-widening base of the right people for the right reasons, at the right times.”
About Thought Leader Select
Thought Leader Select is a Chapel Hill, NC-based private consulting firm serving the biopharmaceutical, medical device, and diagnostics industries with strategies, in-house research, and a suite of engagement tools and support for collaborating with and reaching out to key opinion leaders and centers of excellence in medicine.
Thought Leader Select has supported companies as they develop effective treatments to promote better patient and public health across more than 18 therapeutic areas and 50 diseases and conditions. Thought Leader Select’s customized work strengthens medical marketing initiatives, medical affairs outreach, and payer marketing strategies to support market access, pricing, and reimbursement issues.
Media Contact:
Brian Castle, Director of Global Marketing and Client Relations
Phone: 919-360-9690
E-mail: bcastle@thoughtleaderselect.com
